Tazarotene 0.045% lotion for moderate-to-severe acne in male and female participants: A Phase II Post-hoc analysis

Hilary E. Baldwin, Lawrence J. Green, Leon Kircik, Eric Pierre Guenin, Anya Loncaric Forest, Radhakrishnan Pillai

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


BACKGROUND: In a Phase II study, tazarotene 0.045% lotion was statistically superior to vehicle and comparable to tazarotene 0.1% cream in reducing acne lesions, with fewer treatment-related adverse events (TEAEs) than the cream. OBJECTIVE: We analyzed data from the aforementioned study post-hoc to evaluate the effects of sex on treatment outcomes. METHODS: Participants aged 12 years or older with moderate-to-severe acne were randomized to tazarotene (0.045% lotion or 0.1% cream) or vehicle (lotion or cream) for 12 weeks of double-blind treatment. Outcomes analyzed in male and female subgroups included changes from baseline in inflammatory/noninflammatory lesions and TEAEs. RESULTS: In the intent-to-treat population (94 males and 116 females), reductions in lesion count were greater with tazarotene (lotion or cream) than with vehicle. In participants receiving tazarotene 0.045% lotion, the least-squares mean percent changes from baseline to Week 12 were greater in females than males, but the differences were not statistically significant (inflammatory [−70.3% vs. −56.2%]; noninflammatory [−60.0% vs. −53.2%]). In both females and males, the TEAE incidence was lower with tazarotene 0.045% lotion than 0.1% cream. CONCLUSION: Tazarotene 0.045% lotion substantially reduced acne lesions in both female and male participants. This newest tazarotene formulation might benefit patients who cannot tolerate older formulations or other topical retinoids. Given the relatively small size of this study, however, the results of this post-hoc analysis are intended to be exploratory in nature.

Original languageEnglish
Pages (from-to)E53-E60
JournalJournal of Clinical and Aesthetic Dermatology
Issue number4
StatePublished - 1 Apr 2021


  • Acne
  • Gender
  • Retinoid
  • Sex
  • Topical


Dive into the research topics of 'Tazarotene 0.045% lotion for moderate-to-severe acne in male and female participants: A Phase II Post-hoc analysis'. Together they form a unique fingerprint.

Cite this